Description
Vivimed Labs Ltd. equity shares will be moved from current group to 'B' group effective December 26, 2025.
Summary
BSE has announced that equity shares of Vivimed Labs Ltd. (Scrip Code: 532660) will be transferred to the ‘B’ group effective December 26, 2025. This is a classification change that affects the trading category of the company’s shares on the exchange.
Key Points
- Vivimed Labs Ltd. (Scrip Code: 532660) will be included under ‘B’ group
- Change effective from December 26, 2025
- Notice issued on December 18, 2025
- Trading members informed through Notice No. 20251218-19
- Contact person: Ms. Kinjal More (Cell: +91-7304278788) for clarifications
Regulatory Changes
The equity shares of Vivimed Labs Ltd. are being reclassified from their current group to the ‘B’ group. The B group typically includes companies that do not fall under the most liquid A group category, which may result in different trading parameters and surveillance measures.
Compliance Requirements
Trading members must:
- Take note of the group change effective December 26, 2025
- Update their systems to reflect the new group classification
- Contact Ms. Kinjal More for any clarifications regarding the change
Important Dates
- Notice Date: December 18, 2025
- Effective Date: December 26, 2025
Impact Assessment
The reclassification to ‘B’ group may affect:
- Trading volumes and liquidity perception
- Price band restrictions and circuit filter applicability
- Surveillance measures applicable to the stock
- Investor sentiment and trading behavior
Trading members should prepare for the transition and inform their clients about the group change before the effective date.
Impact Justification
Group change affects trading dynamics and surveillance measures for the stock but does not halt trading